Cellular immune response

PRAME antigen is recognized by autologous cytolyticT lymphocytes (CTL) on HLA class I molecules (Ikeda et al., 1997 PMID: 9047241). CD8 T-cell responses against PRAME were detected directly “ex vivo” in melanoma and leukemia patients (Griffioen et al., 2006 PMID: 16707612; Rezvani et al., 2009 PMID: 18988867). Quintarelli et al., 2011 (PMID: 21278353) were able to generate high avidity CTLs from healthy donors and patients with CML, AML and lymphomas, with anti-tumor activity against HLA-A*02+ PRAME+ tumor cell lines and primary leukemic blasts.